Earnings (Loss) Per Share (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended																12 Months Ended
	Jun. 28, 2014		Mar. 29, 2014		Dec. 28, 2013		Sep. 28, 2013		Jun. 29, 2013		Mar. 30, 2013		Dec. 29, 2012		Sep. 29, 2012		Jun. 28, 2014	Jun. 29, 2013	Jun. 30, 2012
Numerator:
Income from continuing operations																	$ 205.3	$ 441.9	$ 393.0
Income from discontinued operations, net of tax																	0	0	8.6
Net income	$ 131.7	[1]	$ 48.1	[2]	$ (86.0)	[3]	$ 111.4	[4]	$ 118.5	[5]	$ 111.9	[6]	$ 106.0	[7]	$ 105.6	[8]	$ 205.3	$ 441.9	$ 401.6
Denominator:
Weighted average shares outstanding for basic EPS	133.8	[1]	133.7	[2]	98.7	[3]	94.2	[4]	94.0	[5]	94.0	[6]	93.9	[7]	93.6	[8]	115.1	93.9	93.2
Dilutive effect of share-based awards																	0.5	0.6	0.8
Weighted average shares outstanding for diluted EPS	134.3	[1]	134.3	[2]	98.7	[3]	94.7	[4]	94.6	[5]	94.5	[6]	94.5	[7]	94.3	[8]	115.6	94.5	94.1
Antidilutive share-based awards oustanding																	0.1	0.2	0.2

[1] Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.

[2] Includes restructuring charges totaling $19.5 million, write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs.

[3] Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, restructuring charges totaling $14.9 million, write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D of $6.0 million related to Paddock and Rosemont.

[4] Includes Elan transaction costs of $12.0 million, litigation settlement of $2.5 million, and acquisition costs of $1.9 million.

[5] Includes a pre-tax charge to cost of sales of $1.2 million associated with the step-up in value of inventory related to the Rosemont acquisition, $5.6 million of restructuring and other integration-related costs associated with the Velcera acquisition and a $9.0 million impairment charge related to the write-off of IPR&D.

[6] Includes a pre-tax charge to cost of sales of $1.9 million associated with the step-up in value of inventory related to the Rosemont acquisition, approximately $3.1 million of acquisition costs associated with the Rosemont and Velcera acquisitions and a $1.6 million loss related to the sale of the Company's investment securities.

[7] Includes a pre-tax charge to cost of sales of $7.7 million associated with the step-up in value of inventory related to the Sergeant's acquisition, $1.5 million of severance costs associated with the Cobrek acquisition and a $3.0 million loss on the sale of investment related to Cobrek.

[8] Includes a pre-tax charge of approximately $1.9 million of acquisition costs associated with the Sergeant's acquisition.